FDA approves first biosimilar to Neulasta

Author(s):

fda approves first biosimilar neulasta

On June 4, the U.S. Food and Drug Administration (FDA) approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the chance of infection as suggested by febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.

Read more via FDA.gov.

LEAVE A REPLY

Please enter your comment!
Please enter your name here